CLAIM #2610 · AbbVie Inc (ABBV) · 2025Q2 earnings call · Jul 31, 2025

“So as economic conditions improve from current levels, we remain very well positioned for growth over the long term in the aesthetics category.”

Jeffrey Stewart · Chief Commercial Officer

How to check this claim

This claim states no checkable outcome, so Maat records it without grading it.

In context

“s and lower overall consumer sentiment have impacted the aesthetics market, which continues to perform below historical levels. As noted on the first quarter call, we moderated our assumptions for near-term category growth globally, which is tracking largely in line with our expectations. From a competitive perspective, our facial injectable portfolio remains the clear leader with strong market shares globally. Our progress with the Alle loyalty program is going well, and we have robust plans underway to support patient activation. This includes a new BOTOX consumer campaign in the U.S. with ramping second half investment. continued injector training globally and bringing new products to market like TrenibotE, our fast-acting short-duration toxin with commercialization expected next year. So as economic conditions improve from current levels, we remain very well positioned for growth over the long term in the aesthetics category. Moving now to neuroscience, our second largest therapeutic area, where we continue to demonstrate robust growth. Total revenues were approximately $2.7 billion, up 24% on an operational basis. This exceptional performance is driven by continued double-digit operational growth of Vraylar with global sales of $900 million, up 16.3% BOTOX Therapeutic with global revenues of $928 million, up 14.2% Ubrelvy with global sales of $338 million, up 47.2% and QULIPTA with global revenues of $267 million, up 76.9%. Importantly, we recently announced positive results from the head-to-head TEMPLE study comparing QULIPTA to topiramate for migraine prevention. TEMPLE demonstrated that QULIPTA had fewer treatment discontinuations attributed to adverse events as well as a significant reduction in migraine”

Verify independently

SEC filings for ABBV ↗ · Quote is verbatim from the 2025Q2 earnings call.